These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 36813168)
21. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728 [TBL] [Abstract][Full Text] [Related]
22. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132 [TBL] [Abstract][Full Text] [Related]
23. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405 [TBL] [Abstract][Full Text] [Related]
24. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. Jackson WC; Hartman HE; Dess RT; Birer SR; Soni PD; Hearn JWD; Reichert ZR; Kishan AU; Mahal BA; Zumsteg ZS; Efstathiou JA; Kaffenberger S; Morgan TM; Mehra R; Showalter TN; Krauss DA; Nguyen PL; Schipper MJ; Feng FY; Sandler HM; Hoskin PJ; Roach M; Spratt DE J Clin Oncol; 2020 Sep; 38(26):3024-3031. PubMed ID: 32396488 [TBL] [Abstract][Full Text] [Related]
25. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436 [TBL] [Abstract][Full Text] [Related]
26. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Pollack A; Kuban DA; Zagars GK Urology; 2002 Sep; 60(3 Suppl 1):22-30; discussion 30-1. PubMed ID: 12231041 [TBL] [Abstract][Full Text] [Related]
27. Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy. Schiffmann J; Lesmana H; Tennstedt P; Beyer B; Boehm K; Platz V; Tilki D; Salomon G; Petersen C; Krüll A; Graefen M; Schwarz R Strahlenther Onkol; 2015 Apr; 191(4):330-7. PubMed ID: 25471276 [TBL] [Abstract][Full Text] [Related]
28. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Hurwitz MD; Halabi S; Archer L; McGinnis LS; Kuettel MR; DiBiase SJ; Small EJ Cancer; 2011 Dec; 117(24):5579-88. PubMed ID: 22535500 [TBL] [Abstract][Full Text] [Related]
29. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907). Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225 [TBL] [Abstract][Full Text] [Related]
30. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309 [TBL] [Abstract][Full Text] [Related]
31. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
32. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591 [TBL] [Abstract][Full Text] [Related]
33. Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer. Takaha N; Okihara K; Kamoi K; Kimura Y; Yamada T; Kawauchi A; Kobayashi K; Yamazaki H; Nishimura T; Miki T Urol Int; 2011; 87(1):28-34. PubMed ID: 21701133 [TBL] [Abstract][Full Text] [Related]
34. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781 [TBL] [Abstract][Full Text] [Related]
35. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification. Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732 [TBL] [Abstract][Full Text] [Related]
36. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer. Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979 [TBL] [Abstract][Full Text] [Related]
37. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Wang C; Raldow AC; Nickols NG; Nguyen PL; Spratt DE; Dess RT; Yu JB; King CR; Chu FI; Chamie K; Litwin MS; Saigal CS; Reiter RE; Liu ST; Rettig MB; Chang AJ; Steinberg ML; Kupelian PA; Kishan AU Eur Urol Oncol; 2021 Apr; 4(2):327-330. PubMed ID: 31411981 [TBL] [Abstract][Full Text] [Related]